{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:54:54Z","timestamp":1776941694721,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The diagnosis of primary aldosteronism (PA) is comprehensive, which includes case-detection testing, case confirmation followed by subtype classification. In certain instances, such as in the setting of spontaneous hypokalemia, suppressed renin activity (PRA) plus plasma aldosterone concentration (PAC) of &gt; 15 ng\/dL, one may not proceed with confirmatory tests. However, the quality of evidence behind this approach is very low. This study sought to evaluate the proposed \u201csimplified confirmatory pathway\u201d that can spare confirmatory testing for primary aldosteronism by evaluating the diagnostic performances of the various pre-specified PAC thresholds in combination with findings of suppressed renin and spontaneous hypokalemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a multi-center, retrospective diagnostic accuracy cohort-selected cross-sectional study. A total of 133 participants aged 18 years and above underwent saline infusion test between January 2010 to March 2024. The outcome measures comprise of the diagnostic performances of the different index test combinations (baseline PAC, baseline PRA and presence of spontaneous hypokalemia): sensitivity, specificity, negative predictive value, positive predictive value, positive likelihood ratio, negative likelihood ratio, and diagnostic accuracy. Data analysis was performed using SPSS 29.0.1.0 &amp; MedCalc 20.218.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 133 patients who underwent saline infusion test, 88 (66.17%) were diagnosed with PA. A PAC of &gt; 25 ng\/dL plus PRA &lt; 1.0 ng\/dL\/hr with spontaneous hypokalemia showed the highest specificity at 100% (95% CI 90.51%, 100.00%) and positive predictive value at 100% (85.18 \u2013 100.00%). The minimum acceptable combination criteria were determined to be a PAC of &gt; 20 ng\/dL plus PRA &lt; 0.6 ng\/dL\/hr, and presence of spontaneous hypokalemia. It has high specificity (94.59%; 95% CI 81.81%, 99.34%), positive predictive value (93.55%, 95% CI 78.49%, 98.29%), and moderate positive likelihood ratio (LR+) (6.39, 95% CI 1.61, 25.38)<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A hypertensive patient with spontaneous hypokalemia and screening findings of PAC &gt; 20 ng\/dL and suppressed PRA of &lt; 0.6 ng\/ml\/hr, may be classified as \u201covert primary aldosteronism confirmed\u201d and may not need to proceed with dynamic confirmatory testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Protocol registration number<\/jats:title>\n                <jats:p>SRCTN34186253<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-024-01638-w","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T09:11:42Z","timestamp":1720429902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sparing confirmatory testing in primary aldosteronism (SCIPA): a multicenter retrospective diagnostic accuracy study"],"prefix":"10.1186","volume":"24","author":[{"given":"Albert Macaire C.","family":"Ong Lopez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Leo E.","family":"Tiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Collen","family":"Dimayuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver Allan C.","family":"Dampil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erick S.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Marie","family":"Macabuag-Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"issue":"7","key":"1638_CR1","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1210\/jc.2016-1472","volume":"101","author":"SC K\u00e4yser","year":"2016","unstructured":"K\u00e4yser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: A systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101(7):2826\u201335. https:\/\/doi.org\/10.1210\/jc.2016-1472.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1638_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1210\/clinem\/dgz293","volume":"105","author":"Y Hu","year":"2020","unstructured":"Hu Y, Zhang J, Liu W, Su X. Determining the prevalence of primary aldosteronism in patients with new-onset type 2 diabetes and hypertension. The Journal of Clinical Endocrinology & Metabolism. 2020;105(4):1079\u201385. https:\/\/doi.org\/10.1210\/clinem\/dgz293.","journal-title":"The Journal of Clinical Endocrinology & Metabolism."},{"issue":"03","key":"1638_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1055\/a-0857-1620","volume":"51","author":"M Vivien","year":"2019","unstructured":"Vivien M, Deberles E, Morello R, Haddouche A, Guenet D, Reznik Y. Evaluation of biochemical conditions allowing bypass of confirmatory testing in the workup of Primary Aldosteronism: A retrospective study in a French hypertensive population. Horm Metab Res. 2019;51(03):172\u20137. https:\/\/doi.org\/10.1055\/a-0857-1620.","journal-title":"Horm Metab Res"},{"issue":"5","key":"1638_CR4","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"RM Carey","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916. https:\/\/doi.org\/10.1210\/jc.2015-4061.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1638_CR5","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1210\/clinem\/dgaa606","volume":"105","author":"A Vaidya","year":"2020","unstructured":"Vaidya A, Carey RM. Evolution of the primary aldosteronism syndrome: Updating the approach. J Clin Endocrinol Metab. 2020;105(12):3771\u201383. https:\/\/doi.org\/10.1210\/clinem\/dgaa606.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1638_CR6","doi-asserted-by":"publisher","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","volume":"6","author":"JF Cohen","year":"2016","unstructured":"Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. Stard 2015 guidelines for reporting diagnostic accuracy studies: Explanation and elaboration. BMJ Open. 2016;6(11):e012799. https:\/\/doi.org\/10.1136\/bmjopen-2016-012799.","journal-title":"BMJ Open."},{"issue":"1","key":"1638_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13643-019-1131-4","volume":"8","author":"T Mathes","year":"2019","unstructured":"Mathes T, Pieper D. An algorithm for the classification of study designs to assess diagnostic, prognostic and Predictive Test Accuracy in systematic reviews. Systematic Reviews. 2019;8(1):226. https:\/\/doi.org\/10.1186\/s13643-019-1131-4.","journal-title":"Systematic Reviews."},{"issue":"9","key":"1638_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1553-2712.1996.tb03538.x","volume":"3","author":"NM Buderer","year":"1996","unstructured":"Buderer NM. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Academic Emergency Medicine. 1996;3(9):895\u2013900. https:\/\/doi.org\/10.1111\/j.1553-2712.1996.tb03538.x.","journal-title":"Academic Emergency Medicine."},{"issue":"1","key":"1638_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1161\/hypertensionaha.117.10197","volume":"71","author":"Y Song","year":"2018","unstructured":"Song Y, Yang S, He W, Hu J, Cheng Q, Wang Y, et al. Confirmatory tests for the diagnosis of primary aldosteronism. Hypertension. 2018;71(1):118\u201324. https:\/\/doi.org\/10.1161\/hypertensionaha.117.10197.","journal-title":"Hypertension."},{"issue":"7","key":"1638_CR10","doi-asserted-by":"publisher","first-page":"dgaa282","DOI":"10.1210\/clinem\/dgaa282","volume":"105","author":"K Wang","year":"2020","unstructured":"Wang K, Hu J, Yang J, Song Y, Fuller PJ, Hashimura H, et al. Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism. The Journal of Clinical Endocrinology & Metabolism. 2020;105(7):dgaa282. https:\/\/doi.org\/10.1210\/clinem\/dgaa282.","journal-title":"The Journal of Clinical Endocrinology & Metabolism."},{"issue":"4","key":"1638_CR11","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1210\/clinem\/dgz148","volume":"105","author":"H Umakoshi","year":"2019","unstructured":"Umakoshi H, Sakamoto R, Matsuda Y, Yokomoto-Umakoshi M, Nagata H, Fukumoto T, et al. Role of aldosterone and potassium levels in sparing confirmatory tests in primary aldosteronism. J Clin Endocrinol Metab. 2019;105(4):1284\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgz148.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1638_CR12","doi-asserted-by":"publisher","first-page":"dgaa117","DOI":"10.1210\/clinem\/dgaa117","volume":"105","author":"J Kawashima","year":"2020","unstructured":"Kawashima J, Araki E, Naruse M, Kurihara I, Takahashi K, Tamura K, et al. Baseline plasma aldosterone level and renin activity allowing omission of confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab. 2020;105(5):dgaa117. https:\/\/doi.org\/10.1210\/clinem\/dgaa117.","journal-title":"J Clin Endocrinol Metab."}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01638-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-024-01638-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-024-01638-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T09:12:57Z","timestamp":1720429977000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-024-01638-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1638"],"URL":"https:\/\/doi.org\/10.1186\/s12902-024-01638-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"6 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study abided by the Principles of Declaration of Helsinki and was conducted along the Guidelines of the International Conference on Harmonization-Good Clinical Practice (ICH-GCP). The clinical protocol and all relevant documents were thoroughly reviewed and approved by the St. Luke\u2019s Medical Center Institutional Ethics Review Committee (EC Refence No. SL-22004) on February 14, 2022, with a waived informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u201cNot applicable\u201d in this section","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}